OncoMatch/Leukemia — Acute Lymphoblastic (ALL)/KMT2A (MLL) rearrangement
Leukemia — Acute Lymphoblastic (ALL)KMT2A (MLL) rearrangement Clinical Trials
KMT2A (MLL) rearrangements occur in approximately 10% of adult ALL and 70–80% of infant ALL, defining an adverse-risk subgroup with poor outcomes using standard chemotherapy. Revumenib, a menin inhibitor, received FDA approval for relapsed/refractory KMT2A-rearranged acute leukemia in 2024. Trials investigate menin inhibitors in newly diagnosed KMT2A-rearranged ALL, combinations with blinatumomab and inotuzumab, and infant ALL-specific chemotherapy-free approaches.
Top recruiting KMT2A (MLL) rearrangement Leukemia — Acute Lymphoblastic (ALL) trials
Ranked by phase and US site count.
See all trials matched to your profile →Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Princess Maxima Center for Pediatric Oncology
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Janssen Research & Development, LLC
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Tanja Andrea Gruber
More KMT2A (MLL) rearrangement Leukemia — Acute Lymphoblastic (ALL) trials
6 international trials (no US sites)
Browse other molecular targets with active Leukemia — Acute Lymphoblastic (ALL) trials.